Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A1 | P13866 | 1/20 | 0.33 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.33 |
| ▸ | CTNNB1 | P35222 | 4/20 | 0.33 |
| ▸ | WNT3A | P56704 | 4/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
| ▸ | HTR1A | P08908 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18511225 | 0.93 | SLC5A1 (0.34) | SLC5A1SLC5A2CTNNB1WNT3AHTR1A | |
| SCHEMBL1670317 | 0.89 | SLC5A1 (0.34) | SLC5A1SLC5A2CTNNB1WNT3AACHE | |
| SCHEMBL1670051 | 0.85 | — | — | |
| SCHEMBL16727633 | 0.85 | SLC5A2 (0.35) | SLC5A1SLC5A2CTNNB1WNT3ANPC1 | |
| SCHEMBL10177146 | 0.85 | SLC5A2 (0.35) | SLC5A1SLC5A2CTNNB1WNT3ANPC1 | |
| SCHEMBL16730254 | 0.84 | HTR1A (0.34) | SLC5A1SLC5A2HTR1ASLC6A4 | |
| SCHEMBL10226680 | 0.84 | HTR1A (0.34) | SLC5A1SLC5A2HTR1ASLC6A4 | |
| SCHEMBL1671023 | 0.81 | SLC5A2 (0.35) | SLC5A1SLC5A2HTR1ASLC6A4 | |
| SCHEMBL20139724 | 0.80 | SLC5A1 (0.40) | SLC5A1SLC5A2ACHEHTR1A | |
| SCHEMBL20139983 | 0.80 | SLC5A1 (0.40) | SLC5A1SLC5A2ACHEHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8466114-B2 | Glycoside derivatives and uses thereof | NOVARTIS AG (CH) | 2013-06-18 | — | — | US | disclosed |
| US-20120178680-A1 | GLYCOSIDE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2012-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178680-A1 | GLYCOSIDE DERIVATIVES AND USES THEREOF | SLC5A1, SLC5A2, SLC2A1 | SLC5A1 1/4885SLC5A2 2/4885CTNNB1 2680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.